01968nas a2200301   4500000000100000008004100001260001600042653001000058653001900068653001100087653001100098653000900109653001600118653002600134653001700160653002900177653001300206653001800219653001700237100001400254700001500268700001600283245008800299300001100387490000800398520124600406022001401652       1995                            d  c1995 Sep 0910aAdult10aDrug Eruptions10aFemale10aHumans10aMale10aMiddle Aged10aMultivariate Analysis10aRisk Factors10aStevens-Johnson Syndrome10aTanzania10aThioacetazone10aTuberculosis1 aIpuge Y A1 aRieder H L1 aEnarson D A00aAdverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania.  a657-600 v3463 a<p>Because thiacetazone has been linked with serious adverse cutaneous reactions, we undertook 1 year of systematic surveillance for cutaneous thiacetazone-associated adverse reactions within the national tuberculosis programme of Tanzania. For individual cases, we collected information on age, sex, interval between commencing thiacetazone-containing treatment and occurrence of adverse reaction, most severe clinical presentation (toxic epidermal necrolysis, rash without necrolysis, itching without rash), and outcome (dead or alive) within 2 weeks of onset. Univariate and multivariate analyses were done of variables relevant to outcome. 1273 patients with adverse reactions were reported. The frequency of fatal outcome from any cutaneous reaction was 3.1 per 1000 among all tuberculosis patients, and 19.1% among patients with toxic epidermal necrolysis. About 60% of all adverse reactions and deaths occurred within 20 days of starting thiacetazone. Case fatality from adverse cutaneous reactions was considerably less frequent than reported previously, suggesting that improved management might allow retention of thiacetazone in the armamentarium of national tuberculosis programmes even where infection with HIV is prevalent.</p>  a0140-6736